Shots:

• The company reported the results from part A of the P-I/II trial to evaluate MRx-4DP0004 vs PBO in patients with asthma
• The results showed that a greater proportion of patients experienced an 83.3% vs 56.3% reduction in ACQ-6 scores at end of treatment, 50% vs 18.8% reduced the use of SABA rescue medication & 50% vs 31.3% experienced an improvement in AQLQ scores of ≥0.5 from baseline at the end of the treatment period (day 85)
• Additionally, mean measures of lung function remained stable from baseline and throughout the treatment period, was safe and well-tolerated with no TRAEs or serious AEs. The company continues to advance the therapy & plans to enroll patients in part B of the P-I/II trial, based on the part A results

Ref: 4dpharmaplc | Image: 4D Pharma